Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leber congenital amaurosis- gene therapy - IVERIC bio

Next Previous
X
Search
Drug Profile

Leber congenital amaurosis- gene therapy - IVERIC bio

Alternative Names: mini-CEP290; mini-CEP290 Iveric; mini-CEP290: LCA10

Latest Information Update: 01 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer IVERIC bio
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Cep290 protein modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Leber congenital amaurosis

Most Recent Events

  • 28 Aug 2023 Preclinical studies in Leber congenital amaurosis in USA (unspecified route) (Iveric Bio pipeline, August 2023)
  • 11 Jul 2023 IVERIC bio has been acquired by Astellas Pharma
  • 24 Mar 2023 IVERIC bio has patents pending for eye disorder gene therapies in USA, the EPO Countries, China, Japan and certain other jurisdictions, prior to December 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top